Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.
Pharma and biotech takeover activity slumps to a five-year low in 2017.